Notícias

TransMedics Group (NASDAQ:TMDX) outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation. Waleed Hassanein, Tran

Revenue hit $189.9 million with 21% growth as organ transplant volumes surge.

TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.

TransMedics stock slipped on mixed results, but its future remains bright.

TransMedics Group stock has delivered a 170.9% gain over the past five years, yet the broader valuation checks currently lean toward the shares being undervalued rather than fully priced in. With recent returns mixed over shorter periods, the market seems less certain than the long term chart suggests about what the current price of US$80.75 really reflects. The 170.9% return over five years signals that long term holders in TransMedics Group have already seen substantial value creation,...

TransMedics Group Inc (TMDX) posts 21% revenue growth to $190 million, raises full-year guidance, and advances key clinical programs despite margin pressure from strategic investments.

TransMedics Group (NASDAQ:TMDX) reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure. Total revenue for the quarter ended June 30 rose 21% year ov

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics (TMDX) delivered earnings and revenue surprises of -12.00% and +3.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TransMedics Group, Inc. previously announced it would report its Q2 2026 results after the market close on August 4, 2026, alongside an earnings call, while also granting stock options and restricted stock units to new employees under Nasdaq Listing Rule 5635(c)(4). UBS’s recent initiation of analyst coverage, combined with new equity awards aimed at retaining and attracting talent, highlights growing institutional attention to TransMedics’ transplant-focused technology platform and...

TransMedics Group (TMDX) heads into a busy early August, with Q2 2026 results and an earnings call scheduled for August 4 after the market close, drawing fresh attention to the stock. See our latest analysis for TransMedics Group. Recent trading in TransMedics Group reflects this renewed attention, with a 1 day share price return of 6.6% and a 30 day share price return of 18.4%, even as the year to date share price return is down 33.5% and the 1 year total shareholder return is down 35.1%...

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Daniel Markowitz reduced the price target on TMDX to $90 from $100 while maintaining an Outperform rating on […]

Shares are down nearly 45%, but this healthcare innovator may be quietly building the logistics backbone of organ transplantation for decades to come.

Don't wait until they recover.

TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target.

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing sector challenges.

In recent coverage, TransMedics Group’s Organ Care System (OCS) has been highlighted for its role in transforming organ transplant therapy by maintaining organs in near-physiological conditions, while analysts have pointed to solid revenue growth and strong return on equity as key strengths. An interesting angle for investors is how the OCS platform’s potential to extend organ viability may underpin a wider shift in transplant practices and healthcare infrastructure investment. Next, we’ll...

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

Stock performance context for TransMedics Group investors TransMedics Group (TMDX) has drawn attention after a period of weak share performance, with the stock down about 7% over the past day and about 50% over the past 3 months. That setback contrasts with the company’s current fundamentals, including reported revenue of US$635.89 million and net income of US$171.924 million. These figures give investors concrete financial data to weigh against the recent share price slide. See our latest...

TransMedics Group Inc (TMDX) reports a 21% revenue increase while navigating regulatory impacts and competitive pressures.

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]

Forget "sell in May and go away." These stocks are good picks to buy and hold.

TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.

Waleed Hassanein: Thank you so much, Hannah. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

Moby summary of TransMedics Group, Inc.'s Q1 2026 earnings call